Skip to main content
. 2016 Sep 22;7(44):71429–71439. doi: 10.18632/oncotarget.12198

Figure 2. FGFR3 mutation analysis of our squamous differentiated bladder cancer samples (n = 71).

Figure 2

(A) Frequency of FGFR3 mutations (8.5%) in our squamous bladder tumors. (B) Univariate Kaplan-Meier survival curve illustrating recurrence-free survival (RFS) of patients with FGFR3 mutation (dashed gray line) compared to non-mutated tumors (black line). Vertical lines: censored cases.